SK Chemicals' Ginexin Surpasses 600 Billion Won in Cumulative Sales

SK Chemicals announced on the 12th that its ginkgo leaf extract-based pharmaceutical, Ginexin, has achieved cumulative sales of 600 billion won.

At a ceremony held on the 11th at the SK Chemicals headquarters in Seongnam, Gyeonggi Province, celebrating Genexine's cumulative sales reaching 600 billion KRW, Hyunseon Park, Head of Pharma Business (fourth from the left in the photo), is taking a commemorative photo with executives and staff members. SK Chemicals

This is the first time a domestically developed ginkgo leaf extract-based pharmaceutical has reached such a milestone. Since its launch, the total number of tablets sold has reached approximately 3.5 billion. If lined up end to end, this would stretch about 50,000 kilometers—enough to circle the Earth once.

Since its release in 1992, Ginexin has been used for 34 years and has established itself as Korea's leading ginkgo leaf extract-based pharmaceutical. According to UBIST, a pharmaceutical market research institution, the domestic market for ginkgo leaf extract-based pharmaceuticals is expected to reach about 92.6 billion won in 2025. Ginexin holds a 37% market share and recorded annual sales of 34.4 billion won in this segment.

Over the past five years, annual sales figures were 18.4 billion won in 2021, 26.2 billion won in 2022, 29.7 billion won in 2023, 30.9 billion won in 2024, and 34.4 billion won last year, with an average annual sales of about 27.9 billion won and an average annual growth rate of 17%. Ginexin has maintained the top spot in sales since 2002.

Symbolized by a green ginkgo leaf, Ginexin is a standardized pharmaceutical manufactured from the active ingredients of ginkgo leaves. It is used to improve blood circulation, memory decline, reduced concentration, dizziness, and tinnitus, thanks to its vasodilatory, blood flow enhancement, and antioxidant effects.

The company analyzed that Ginexin’s recent growth is attributable not only to its general role in improving blood circulation, but also to increased attention on its potential to improve cognitive function by enhancing cerebral blood flow. In particular, as related clinical evidence accumulates, its use in medical settings is expanding.

SK Chemicals plans to respond to these changes by actively promoting Ginexin’s clinical evidence and product characteristics to the medical community and expanding marketing activities not only to neurologists, but also to internists and general practitioners, thereby continuing to increase its market share.

Hyunseon Park, Head of the Pharma Business at SK Chemicals, said, “Ginexin is a pharmaceutical that addresses various conditions caused by blood circulation issues, and we plan to continuously build evidence for its effectiveness in vascular-related areas, including cognitive function. We will strengthen marketing to both the general public and medical professionals to further solidify Ginexin’s position as the top ginkgo leaf extract-based pharmaceutical.”

Meanwhile, SK Chemicals has released new advertising content featuring a conversation between a mother and AI, showcasing Ginexin’s efficacy, through YouTube and other media outlets.

This content was produced with the assistance of AI translation services.